Journal of Clinical Endocrinology & Metabolism, Vol 80, 1837-1844, Copyright © 1995 by Endocrine Society

ARTICLES

Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas

J Epelbaum, J Bertherat, G Prevost, C Kordon, W Meyerhof, I Wulfsen, D Richter and PF Plouin
INSERM U-159, Centre P. Broca, Paris, France.

SRIH receptors were quantified by radioautography in 33 pheochromocytomas and 5 normal adrenals. Binding was evenly distributed over the tumors, whereas it was more intense in adrenal medulla than cortex. Binding levels were significantly higher in tumoral than in normal tissue, but did not differ among tumors. At 100 nmol/L, SRIH-14 and octreotide (or BIM23014 in cross-linking experiments to a 57- kilodalton component) comparably displaced SRIH binding, BIM23042 and BIM23052 were less potent, and BIM23056 was inefficient. In increasing doses, the rank order of potency was SRIH-14 > SRIH-28 > octreotide > BIM23052 >> BIM23042 >> > BIM23056. All five species of SRIH receptor (SSTR1-5) messenger ribonucleic acids (mRNAs) were measurable in pheochromocytomas and normal adrenals, SSTR2 and SSTR4 mRNA were the most expressed moieties. The proportion of SSTR5 mRNA species was higher in normal adrenals (21%) than in pheochromocytomas (6%). In the presence of guanylylimidodiphosphate, SRIH binding was reduced by 83%. However, SRIH did not alter basal or forskolin-stimulated adenylyl cyclase activity. Taken together, these pharmacological and molecular data indicate that SRIH binding on pheochromocytomas depends on a mixed population of receptors, mainly of the SSTR2 and SSTR4 subtypes, efficiently coupled to G proteins, but not to adenylyl cyclase inhibition.

This article has been cited by other articles:

				I. Ilias and K. Pacak Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 479 - 491. [Full Text] [PDF]

				J. Bertherat, F. Tenenbaum, K. Perlemoine, C. Videau, J. L. Alberini, B. Richard, B. Dousset, X. Bertagna, and J. Epelbaum Somatostatin Receptors 2 and 5 Are the Major Somatostatin Receptors in Insulinomas: An in Vivo and in Vitro Study J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5353 - 5360. [Abstract] [Full Text] [PDF]

				J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]

				L. J. Hofland and S. W. J. Lamberts The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance Endocr. Rev., February 1, 2003; 24(1): 28 - 47. [Abstract] [Full Text] [PDF]

				E. van der Harst, W. W. de Herder, H. A. Bruining, H. J. Bonjer, R. R. de Krijger, S. W. J. Lamberts, A. H. van de Meiracker, F. Boomsma, T. Stijnen, E. P. Krenning, et al. [123I]Metaiodobenzylguanidine and [111In]Octreotide Uptake in Benign and Malignant Pheochromocytomas J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 685 - 693. [Abstract] [Full Text]

				C. J. Anderson, F. Dehdashti, P. D. Cutler, S. W. Schwarz, R. Laforest, L. A. Bass, J. S. Lewis, and D. W. McCarthy 64Cu-TETA-Octreotide as a PET Imaging Agent for Patients with Neuroendocrine Tumors J. Nucl. Med., February 1, 2001; 42(2): 213 - 221. [Abstract] [Full Text]

				C. C. Raggi, M. Maggi, D. Renzi, A. Calabrò, M. L. Bagnoni, P. Scaruffi, G. P. Tonini, M. Pazzagli, B. De Bernardi, G. Bernini, et al. Quantitative Determination of sst2 Gene Expression in Neuroblastoma Tumor Predicts Patient Outcome J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3866 - 3873. [Abstract] [Full Text]

				J. C. Reubi, B. Waser, Q. Liu, J. A. Laissue, and A. Schonbrunn Subcellular Distribution of Somatostatin sst2A Receptors in Human Tumors of the Nervous and Neuroendocrine Systems: Membranous Versus Intracellular Location J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3882 - 3891. [Abstract] [Full Text]

				S. Froidevaux, A. Heppeler, A. N. Eberle, A.-M. Meier, M. Hausler, C. Beglinger, M. Behe, P. Powell, and H. R. Macke Preclinical Comparison in AR4-2J Tumor-Bearing Mice of Four Radiolabeled 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid-Somatostatin Analogs for Tumor Diagnosis and Internal Radiotherapy Endocrinology, September 1, 2000; 141(9): 3304 - 3312. [Abstract] [Full Text] [PDF]

				N. Baou, M. Bouras, J.-P. Droz, M. Benahmed, and S. Krantic Evidence for a selective loss of somatostatin receptor subtype expression in male germ cell tumors of seminoma type Carcinogenesis, April 1, 2000; 21(4): 805 - 810. [Abstract] [Full Text] [PDF]

				L. Groussin, J. F. Massias, X. Bertagna, and J. Bertherat Loss of Expression of the Ubiquitous Transcription Factor cAMP Response Element-Binding Protein (CREB) and Compensatory Overexpression of the Activator CREM{tau} in the Human Adrenocortical Cancer Cell Line H295R J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 345 - 354. [Abstract] [Full Text]

				T. J. Gillespie, A. Erenberg, S. Kim, J. Dong, J. E. Taylor, V. Hau, and T. P. Davis Novel Somatostatin Analogs for the Treatment of Acromegaly and Cancer Exhibit Improved In Vivo Stability and Distribution J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 95 - 104. [Abstract] [Full Text]